<DOC>
	<DOCNO>NCT00609622</DOCNO>
	<brief_summary>This study compare safety efficacy sunitinib combination FOLFOX versus bevacizumab combination FOLFOX treatment patient metastatic colorectal cancer treat .</brief_summary>
	<brief_title>Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer</brief_title>
	<detailed_description>The study terminate April 26 , 2010 due lack efficacy , determine interim analysis data April 2010 , show study meet primary endpoint demonstrate statistically significant improvement PFS . The decision terminate trial base safety concern .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Adenocarcinoma colon rectum locally advance metastatic disease Evidence measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) Eastern Cooperative Oncology Group ( ECOG ) 0 1 Previous treatment Sutent , Avastin , systemic therapy locally advance metastatic colorectal cancer Less 6 month since completion adjuvant chemotherapy documentation recurrent disease History cardiac disease Brain mets</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>metastatic colorectal cancer sunitinib ( Sutent ) bevacizumab ( Avastin ) randomize study</keyword>
</DOC>